Regentis Biomaterials (NYSE American: RGNT) is advancing its Gelrin C hydrogel as a practical regenerative medicine solution for cartilage damage, potentially addressing the significant clinical and economic burden associated with knee osteoarthritis (OA). Gelrin C is a cell-free, off-the-shelf hydrogel administered in a single 10-minute procedure, designed to support cartilage regeneration while avoiding the multiple surgeries, specialized laboratory processing, and higher costs linked to some cell-based therapies.
With approximately 470,000 knee cartilage repair procedures performed annually in the U.S., representing an estimated $3 billion market, the company believes Gelrin C could offer a more scalable approach that fits existing surgical workflows and addresses cartilage defects before they progress to costly OA. The annual U.S. economic burden of knee OA is estimated to range from approximately $5.7 billion to $15 billion, with lifetime costs for affected patients potentially exceeding $140,000. By intervening early with a single-stage procedure, Regentis aims to preserve joint health and potentially delay or prevent more expensive degenerative disease.
Gelrin C is based on Regentis’ proprietary Gelrin platform technology, which uses synchronized, degradable hydrogel implants to regenerate damaged or diseased tissue, including inflamed cartilage and bone. The hydrogel is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. As a cell-free, off-the-shelf treatment, Gelrin C could fill a gap in the current market where no such option is available for the approximately 470,000 annual cartilage repair cases.
Regentis is advancing Gelrin C toward commercialization, leveraging its clinical data and single-stage design to position itself for growing demand for regenerative treatments. The company’s focus on orthopedic treatments aligns with a broader shift toward therapies that restore joint health and improve quality of life. For more information, the full article is available at https://ibn.fm/yPKU2, and the latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT.
Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K or any updates in subsequent filings with the SEC. Undue reliance should not be placed on forward-looking statements, which are based on information available as of the date hereof. All parties undertake no duty to update this information unless required by law.
